De Novo device
allay Nerve Cap (TL5515-1)
Tulavi Therapeutics, Inc. · In Situ Polymerizing Peripheral Nerve Cap (SBG, Class II) · First FDA decision Jul 16, 2024, newest Sep 29, 2025Peripheral neuropathy and nerve injury
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
20
Naming "allay"
MAUDE reports
2
Brand "allay", since 2015
PubMed studies
1,017
Mentioning "allay"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing allay Nerve Cap (TL5515-1)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K252051 · Decided Sep 29, 2025 · 90 days after receipt
Device type: In Situ Polymerizing Peripheral Nerve Cap (SBG) · Neurology & Neurosurgery
- allay Nerve CapNew device typeDe Novo
DEN230061 · Decided Jul 16, 2024 · 308 days after receipt
Device type: In Situ Polymerizing Peripheral Nerve Cap (SBG) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Peripheral Nerve Injections and Procedures for Chronic PainLocal determinationIn effectL40265Noridian Healthcare Solutions, LLCUpdated Oct 15, 2026
- Peripheral Nerve Injections and Procedures for Chronic PainLocal determinationIn effectL40300WPS Insurance CorporationUpdated Oct 15, 2026
- Peripheral Nerve Injections and Procedures for Chronic PainLocal determinationIn effectL40267Wellpoint FederalUpdated Oct 14, 2026
- Peripheral Nerve Injections and Procedures for Chronic PainLocal determinationIn effectL40261CGS Administrators, LLCUpdated Oct 12, 2026
- Peripheral Nerve Injections and Procedures for Chronic PainLocal determinationIn effectL40263Palmetto GBAUpdated Oct 12, 2026
- Nerve Blocks for Peripheral NeuropathyLocal determinationIn effectL35249CGS Administrators, LLCUpdated Apr 29, 2026
- Peripheral Nerve StimulationLocal determinationIn effectL34328Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Peripheral Nerve Blocks and Procedures for Chronic PainProposed local determinationProposedDL40263Palmetto GBAUpdated Sep 19, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "allay", any status and sponsor, newest update first.
- Alleviant ALLAY-HFrEF StudyPivotal-lookingRecruiting
Alleviant Medical, Inc.Not on our public-company list
NCT06812533 · 350 participants (planned) · Start Mar 10, 2025 · Primary completion Dec 2028
Device: Alleviant ALV1 System · For: Heart Failure
Sites: Los Angeles, California; Sacramento, California; San Diego, California · 70 sites in all
- Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success StudyRecruiting
Tulavi Therapeutics,Inc.Not on our public-company list
NCT07246980 · 1,000 participants (planned) · Start May 6, 2026 · Primary completion Jan 1, 2029
Device: Nerve Cap · For: Peripheral Nerve Injuries
Sites: Redwood City, California; Englewood, Colorado; Orlando, Florida · 5 sites in all
Intressa Vascular SANot on our public-company list
NCT06675617 · 72 participants (planned) · Start Oct 30, 2024 · Primary completion Jun 2027
Device: Allay Aortic Stent · For: Type B Aortic Dissection
Sites: Salzburg, Austria; Genk, Belgium; Leuven, Belgium · 21 sites in all
17 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "allay", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code SBG
2 reports: 0 malfunction, 2 injury, 0 death
Newest reports for this brand
- ALLAY NERVE CAPInjury
3027562169-2026-00001 · Received Jun 26, 2026 · Event dated Feb 12, 2026
Device type: In Situ Polymerizing Peripheral Nerve Cap (SBG)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Wound Dehiscence
- ALLAY NERVE CAPInjury
3027562169-2026-00002 · Received Jun 26, 2026 · Event dated May 7, 2026
Device type: In Situ Polymerizing Peripheral Nerve Cap (SBG)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Wound Dehiscence
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "allay"[tiab]. The summary above synthesizes these.
- Pediatric mastocytosis.
Hussain SH · Curr Opin Pediatr · 2020Review
- Paraben Toxicology.
Fransway AF, Fransway PJ, Belsito DV, et al. · Dermatitis · 2019Review
- AllergyWatch.
Fineman SM, Khan DA, Oppenheimer JJ · Ann Allergy Asthma Immunol · 2019
- [Not Available].
Byk C, Masello S · J Int Bioethique Ethique Sci · 2021
- Transplantation.
Calne RY · J Med Ethics · 1975
- Neurodevelopmental toxicology.
Schmid C, Rotenberg JS · Neurol Clin · 2005Review
- Pediatric Dentistese.
Asokan S, Nuvvula S · J Indian Soc Pedod Prev Dent · 2017Review
- Managing the menopause.
Hillard A · Nurs Stand · 1998Research Support, Non-U.S. Gov't, Review
- Vasectomy.
Brownlee HJ, Tibbels CK · J Fam Pract · 1983
- Nevus Depigmentosus: An Update.
Kansal NK · Skinmed · 2019Review
- Epidemics in perspective.
Valdiserri RO · J Med Humanit Bioeth · 1987
- Odor blocking of stress hormone responses.
Lee EJ, Saraiva LR, Hanchate NK, et al. · Sci Rep · 2022Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.